Healthcare / Drug Manufacturers - Specialty & GenericTel Aviv
$312.00
+63.50 (+21.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-56.3M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$171M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.0%
↓Gross Margin
12.3%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.4%
FCF CAGR
-25.0%
FCF margin
4.9%
FCF / Net income
-0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $270.2M · net income $-35.7M · FCF $13.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $270.2M | $270.2M | $238.8M | $355.6M | $388.7M |
| Net Income | $-35.7M | $-35.7M | $-67.8M | $-62.0M | $44.8M |
| EBITDA | $-7.3M | $-7.3M | $-51.3M | $-23.9M | $70.2M |
| EPS | — | — | -1.48 | -1.36 | 0.99 |
| Gross Margin | 12.3% | 12.3% | 12.7% | 29.6% | 39.9% |
| Operating Margin | 2.5% | 2.5% | -18.9% | 10.6% | 10.6% |
| Net Margin | -13.2% | -13.2% | -28.4% | -17.4% | 11.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.53 | 0.43 | 0.51 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.3M | $13.3M | $-71.3M | $-56.3M | $31.5M |
| Returns | |||||
| ROE | -9.0% | -9.0% | -17.1% | -13.6% | 8.9% |
| Valuation | |||||
| P/E | — | — | — | — | 1354.55 |
| EV/EBITDA | — | — | — | — | 866.30 |
| P/B | 43.03 | 43.03 | 70.96 | 49.46 | 121.32 |
| Growth & Yield | |||||
| Revenue Growth | 13.1% | 13.1% | -32.8% | -8.5% | — |
| EPS Growth | — | — | -8.8% | -237.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.48 → n/d
Residual
-32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.